[Featured Stock] Gold Pacific Expected to Enter Overseas Market with COVID-19 Treatment 50 Times More Effective Than Remdesivir

[Asia Economy Reporter Yoo Hyun-seok] Gold Pacific's stock price continues to rise. The news that its subsidiary APRG received approval for Phase 1 clinical trials of a novel coronavirus (COVID-19) treatment in India appears to have influenced the stock price.

As of 10:49 AM on the 12th, Gold Pacific was trading at 2,255 KRW, up 13.60% (270 KRW) compared to the previous trading day.

Gold Pacific's subsidiary APRG successfully obtained approval from the Central Drugs Standard Control Organization (CDSCO) of India for Phase 1 clinical trials of the COVID-19 treatment candidate 'APRG64.'

APRG plans to begin clinical trials within this year targeting healthy subjects and aims to complete Phase 1 trials by the first half of next year at the latest. Upon completion of Phase 1, Phase 2 trials targeting mild and moderate patients will be conducted simultaneously in India and domestically. The company plans to pursue overseas market entry for the COVID-19 treatment next year.

A Gold Pacific official stated, "Since the efficacy of the COVID-19 treatment has been verified, we expect the new drug development through clinical trials to proceed smoothly." He added, "The consortium, led by Kyung Hee University Industry-Academic Cooperation Foundation, will have ZenenCell responsible for Phase 1 trials, Korea Pharmaceutical Research Institute as the clinical trial contract research organization (CRO), and Korea Pharma handling drug production."

APRG64 was developed by Professor Kang Se-chan, director of the Biomedical Center at Kyung Hee University. It has been reported to be over 50 times more effective in blocking cell entry and inhibiting post-infection proliferation than Remdesivir, which was the first COVID-19 treatment approved by the U.S. Food and Drug Administration (FDA).

This content was produced with the assistance of AI translation services.